Recent Updates
Recently added Catalysts
MNKD Positive Sentiment Score: 65/100

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Key Takeaway: MannKind Corporation has announced that it will release its second quarter 2025 financial results on August 6, 2025, before the market opens. A webcast is scheduled to begin at 9:00 a.m. Eastern Time, where the company will discuss its results and provide a business update. MannKind specializes in developing inhaled therapeutic products aimed at addressing conditions such as diabetes and pulmonary diseases, showcasing its commitment to innovative healthcare solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • MannKind Corporation is committed to addressing serious unmet medical needs.
  • The company focuses on innovative inhaled therapeutic products.
  • MannKind offers rapid and convenient delivery of medicines.

Full Press Release Details

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025.
MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Tags

Frequently Asked Questions

When will MannKind release its Q2 2025 financial results?

MannKind will release its Q2 2025 financial results on August 6, 2025.

What time does MannKind's webcast start?

The webcast begins at 9:00 a.m. Eastern Time.

How can I access the webcast for MannKind's financial results?

The webcast can be accessed via MannKind’s investor website.

What is MannKind Corporation's focus?

MannKind focuses on developing inhaled therapeutics for unmet medical needs.

What diseases does MannKind aim to address?

MannKind targets diseases like diabetes, NTM lung disease, and pulmonary fibrosis.

Last updated: Jul 30, 2025